Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whether the PRRs of the C-type lectin receptor (CLR) family including Dectin-2 may be involved in the pathogenesis of atherosclerosis remains largely unknown.
|
30867470 |
2019 |
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whether the PRRs of the C-type lectin receptor (CLR) family including Dectin-2 may be involved in the pathogenesis of atherosclerosis remains largely unknown.
|
30867470 |
2019 |
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we show that a toll-like receptor (TLR) and C-type lectin receptor (CLR) agonist pairing of monophosphoryl lipid A (MPL) and trehalose-6,6'-dicorynomycolate (TDCM) effectively inhibits tumor growth and ascites development in a mouse model of aggressive mammary cancer-induced peritoneal carcinomatosis.
|
30224373 |
2019 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the in vivo pharmacokinetics of <sup>124</sup>I-CLR1404 (CLR 124) and estimated theranostic dosimetry for <sup>131</sup>I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.
|
30926646 |
2019 |
Carcinomatosis of peritoneal cavity
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we show that a toll-like receptor (TLR) and C-type lectin receptor (CLR) agonist pairing of monophosphoryl lipid A (MPL) and trehalose-6,6'-dicorynomycolate (TDCM) effectively inhibits tumor growth and ascites development in a mouse model of aggressive mammary cancer-induced peritoneal carcinomatosis.
|
30224373 |
2019 |
Ewings sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the in vivo pharmacokinetics of <sup>124</sup>I-CLR1404 (CLR 124) and estimated theranostic dosimetry for <sup>131</sup>I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.
|
30926646 |
2019 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the in vivo pharmacokinetics of <sup>124</sup>I-CLR1404 (CLR 124) and estimated theranostic dosimetry for <sup>131</sup>I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.
|
30926646 |
2019 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we evaluated the in vivo pharmacokinetics of <sup>124</sup>I-CLR1404 (CLR 124) and estimated theranostic dosimetry for <sup>131</sup>I-CLR1404 (CLR 131) MRT in murine xenograft models of the pediatric solid tumors neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.
|
30926646 |
2019 |
Huntington Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
DCLK3 also produced beneficial effects on motor symptoms in a knock-in mouse model of Huntington's disease.
|
29534157 |
2018 |
Leishmaniasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, little is known about the function of the CLR Dectin-1 in modulating Th1- or Th2-type immune responses by DC subsets in leishmaniasis.
|
29535708 |
2018 |
Migraine Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system.
|
30550780 |
2018 |
Secondary malignant neoplasm of lung
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In vivo antitumor efficacy was tested by injecting nude mice bearing either MDA-MB-231-luc orthotopic xenografts or lung metastases with 74 MBq (3.7 GBq/kg) of CLR 125 or an equivalent mass amount of nonradiolabeled CLR 125.
|
29641256 |
2018 |
Motor symptoms
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
DCLK3 also produced beneficial effects on motor symptoms in a knock-in mouse model of Huntington's disease.
|
29534157 |
2018 |
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeted radionuclide therapy with CLR 125 displayed significant antitumor efficacy in vivo, suggesting promise for treatment of TNBC micrometastases.
|
29641256 |
2018 |
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeted radionuclide therapy with CLR 125 displayed significant antitumor efficacy in vivo, suggesting promise for treatment of TNBC micrometastases.
|
29641256 |
2018 |
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We selected five SNPs from among the CLR variants (rs77035639, rs3815524, rs75380157, rs574603859, and rs147565266) and one RAMP2 SNP (rs753152), which were associated with stroke, for analysis.
|
28904253 |
2017 |
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA.
|
26275430 |
2016 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results highlight the hitherto poorly understood mechanism of Kupffer cell-mediated control of metastasis that is mediated by the CLR innate receptor family, with implications for the development of anticancer therapy targeting CLRs.
|
27872290 |
2016 |
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, the present findings suggest that synovial macrophages are the major producers of IL-1β and regulators of CLR in OA mice.
|
26400621 |
2016 |
Staphylococcal Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
For CLR and the remaining subtypes, links among the 3 methods were generally poor.Bovine Staph. aureus is highly clonal and a few clones predominate.Animal Staph. aureus always evolve from human strains, such that every human strain may be the ancestor of a novel animal-adapted strain.
|
26601578 |
2016 |
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, macrophage C-type lectin, a CLR known to be complex with Dectin-2, also contributes to the suppression of liver metastasis.
|
27872290 |
2016 |
Malignant Pleural Mesothelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Real time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to assess the steady-state levels of AM, CLR, RAMP2 and RAMP3 messenger RNA (mRNA) transcripts in normal pleural tissue (n=5) and MPM (n=24).
|
26762744 |
2016 |
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, since RAMP-receptor interfaces are pharmacologically tractable, it may be possible to develop compounds targeting the RAMP1/CLR interface to assist in the treatment of asthma.
|
25010197 |
2014 |
Allergic asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, we found that a 50% reduction of CLR, the G-protein receptor component of the CGRP receptor, also ameliorated airway resistance and inflammation in this model of allergic asthma.
|
25010197 |
2014 |
Neoplasms, Vascular Tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
We therefore investigated the diagnostic/prognostic use for CLR in human tumor types that may rely on adrenomedullin signaling and in clear cell renal cell carcinoma (RCC), a highly vascular tumor, in particular.
|
23969937 |
2013 |